Three-component treatment of muscle-invasive bladder cancer: Case of successful use in patient with stage IV of disease
https://doi.org/10.33667/2078-5631-2022-5-46-53
Abstract
Treatment of bladder cancer is a traditional problem of modern oncology, given the property of this disease to develop in patients of the older age group. For those patients who cannot be offered radical cystectomy because of the anesthetic risks or who refuse it, trimodality therapy, including transurethral resection of the maximum volume and a radical course of chemoradiation therapy, looks like a worthy alternative to radical surgery. This article contains a review of the recent publications on the issue voiced in it, as well as a clinical example of the effectiveness of radiotherapy in a patient with an initially metastatic bladder cancer.
About the Authors
S. V. Medvedev
Moscow Research Institute n. a. P. A. Herzen – a Branch of the National Medical Research Centre of Radiology
Russian Federation
Russian Federation
Medvedev Sergey V., PhD Med, senior researcher at Dept of Neuroradiology, Department of Radiation Therapy
Moscow
A. V. Khachaturian
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Khachaturyan Alexander V., PhD Med, researcher at Surgical Dept No. 4 (Oncourology)
Moscow
D. S. Romanov
Centre for Innovative Medical Technologies Co.; Central Clinical Hospital ‘Russian Railways – Medicine; Moscow State University of Medicine and Dentistry n. a. A. I. Evdokimov
Russian Federation
Russian Federation
Romanov Denis S., PhD Med, deputy CEO for scientific activity, oncologist, head of Dept of Radiology, assistant of Dept of Oncology and Radiation Therapy
Moscow
SPIN code: 1662–8411
V. V. Prokopyeva
Russian National Research Medical University n. a. N. I. Pirogov
Russian Federation
Russian Federation
Prokopyeva Victoria V., 6th year student of Faculty of Medicine
Moscow
References
1. Kaprin A. D., Starinskiy V. V., Shachzadova A. O. The condition of cancer care to the population in 2019. Moscow, 2020. (In Russ.)
2. Kotov S. V., Khachatryan A. L., Guspanov R. I., et al. Evaluation of surgical complications incidence after radical cystectomy. Cancer Urology. 2018;14(4):95–102. (In Russ.)
3. Matveev B. P. Clinical oncourology. Moscow, ABV-press, 2011. (In Russ.)
4. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
5. Novotny V., Froehner M., May M., et al. Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World Journal of Urology. 2015. Nov; 33 (11): 1753–61. PMID: 25663359. DOI: 10.1007/ s00345–015–1502-y.
6. Ku J. H., Kim M., Jeong C. W., et al. Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of Korean patients. International Journal of Radiation oncology, biology, physics. 2014. Aug 1; 89 (5): 1032–1037. PMID: 25035206. DOI: 10.1016/j.ijrobp.2014.04.049.
7. Christodouleas J. P., Baumann B. C., He J., et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer 2014 Apr 15; 120 (8): 1272–80. PMID: 24390799. DOI: 10.1002/cncr.28544.
8. Sagros P., Baumann B. C., Eapen L., et al. Risk factors for locoregional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic review and frame-work for adjuvant radiotherapy. Cancer Treatment Reviews. 2018. Nov; 70: 88–97. P. 88–97. PMID: 30125800. PMCID: PMC 7441580. DOI: 10.1016/j.ctrv.2018.07.011.
9. Zaghloul M. S., Awwad H. K., Akoush H. H., et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease-free survival through improving local control. International Journal of Radiation oncology, biology, physics. 1992. 23 (3): 511–7. PMID: 1612951. DOI: 10.1016/0360–3016(92)90005–3.
10. Zaghloul M. S., Christodouleas J. P., Smith A., et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy. JAMA Surgery. 2018 Jan. 17; 153 (1): e174591. PMID: 29188298. DOI: 10.1001/jamasurg.2017.4591.
11. Iwata T., Kimura S., Abufaraj M., et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urologic Oncology. 2019. Oct; 37 (10): 659–671. PMID: 31255542. DOI: 10.1016/j.urolonc.2019.05.021.
12. Shipley W. U., Kaufman D. S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002. Jul; 60 (1): 62–7. PMID: 12100923. DOI: 10.1016/s0090–4295(02)01650–3.
13. Shipley W. U., Winter K. A., Kaufman D. S., et al. Phase III trial of neoadjuvant chemotherapy for patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. Journal of clinical oncology. 1998. Nov; 16 (11): 3576–83. PMID: 9817278. DOI: 10.1200/JCO.1998.16.11.3576.
14. Rödel C., Weiss C., Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006 Dec 10; 24 (35): 5536–5544. PMID: 17158539. DOI: 10.1200/JCO.2006.07.6729
15. Krause F. S., Walter B., Ott O. J. et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011 Mar; 31(3): 985–90. PMID: 21498726
16. Ott O. J., Rödel C., Weiss C., et al. Radiochemotherapy for bladder cancer. Clin Oncol (R Coll Radiol). 2009 Sep; 21(7): 557–65. PMID: 19564101. DOI: 10.1016/j.clon.2009.05.005.
17. Rödel C., Grabenbauer G. G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. Journal of clinical oncology. 2002. Jul 15; 20 (14): 3061–71. PMID: 12118019. DOI: 10.1200/JCO.2002.11.027.
18. Efstathiou J. A., Spiegel D. Y., Shipley W. U., et al. Long-term outcomes of selective bladder preservation by combined modality therapy for invasive bladder cancer: the MGH experience. European Urology. 2012. Apr; 61 (4): 705–11. PMID: 22101114. DOI: 10.1016/j.eururo.2011.11.010.
19. Giacalone N. J., Shipley W. U., Clayman R. H., et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. European Urology. 2017. Jun; 71 (6): 952–960. PMID: 28081860. DOI: 10.1016/j.eururo.2016.12.020.
20. Tkachev S. I., Figurin K. M., Medvedev S. V., Matveev V. B. Efficiency of conformal and conventional radiation therapy in organ-preserving treatment of patients with invasive bladder cancer. Medical radiology and radiation safety. 2010. No. 6. P. 39–45. (In Russ.)
21. Popov A. M., Grishin G. N., Donichkina E. A., Karjakin O. B. Organ-preserving treatment of invasive bladder cancer. Available at: http://oncologic.narod.ru/ journals/oncouro/ol.html (In Russ.)
22. Sallum S. J. Organ-preserving treatment of bladder cancer T2N 0M0. Abstract of the dissertation of the candidate of medical sciences. Moscow; 2005. (In Russ.)
23. Efstathiou J. A., Bae K., Shipley W. U., et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. Journal of clinical oncology. 2009. Sep 1; 27 (25): 4055–61. PMID: 19636019. DOI: 10.1200/JCO.2008.19.5776.
24. Williams S. B., Shan Y., Jazzar U., et al. Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer. JAMA Surgery. 2018. Oct 1; 153 (10): 881–889. PMID: 29955780. DOI: 10.1001/jamasurg.2018.1680.
25. Bulychkin P. V., Tkachev S. B., Nazarenko A. V., Matveev V. B. The method of radiation therapy for patients with recurrent prostate cancer after radical prostatectomy with the presence of metastases in the regional and retroperitoneal lymphatic nodes. Available at: https://patenton.ru/patent/RU 2711620C 1. (In Russ.)
26. Milano M. T., Biswas T., Simone C.B 2nd, Lo S. S. Oligometastases: history of a hypothesis. Annals of Palliative Medicine. 2021;10(5): 5923–5930. PMID: 32279519. DOI: 10.21037/apm.2020.03.31.
27. Guckenberger M., Lievens Y., Bouma A.B, et al. Characterisation and classification of oligometastatic disease: A European society for radiotherapy and oncology and European organization for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020. Jan; 21 (1): e18–e28. PMID: 31908301. DOI: 10.1016/S1470–2045(19)30718–1.
28. Rompré-Brodeur A., Shinde-Jadhav S., Ayoub M., et al. PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects. Molecular cancer therapeutics. 2020 Jan; 19 (1): 211–220. PMID: 31534011. DOI: 10.1158/1535–7163.MCT-18–0986.
29. Wilkins A., Ost P., Sundahl N. Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer? Clinical Oncology. 2021 Jun; 33 (6): 407–414. PMID: 33726945. DOI: 10.1016/j.clon.2021.02.014.
30.
Review
For citations:
Medvedev S.V., Khachaturian A.V., Romanov D.S., Prokopyeva V.V. Three-component treatment of muscle-invasive bladder cancer: Case of successful use in patient with stage IV of disease. Medical alphabet. 2022;1(5):46-53. (In Russ.) https://doi.org/10.33667/2078-5631-2022-5-46-53
Views:
216
Email this article 